Rate My Professor Kylie Mansfield

Her academic interests encompass bladder physiology and pharmacology, with specializations in overactive bladder, detrusor overactivity, ATP signaling via purinergic receptors and connexin hemichannels in urothelial cells, and responses to inflammatory cytokines and uropathogenic bacteria. Mansfield examines antimicrobial resistance trends in urinary pathogens like Escherichia coli and Enterobacter, including seasonal variations and gender differences, alongside evaluations of non-antibiotic therapies such as cranberry, D-mannose, and NSAIDs for uncomplicated urinary tract infections. Complementary research addresses nutrition competencies and education in medicine, interprofessional health professions education, longitudinal trends in Australia's rural and regional health workforce using data from the Australian Health Practitioner Regulation Agency, and end-of-life sedation protocols, exemplified by the DREAMS trial comparing dexmedetomidine and midazolam.

With 138 publications and over 2,750 citations, her key works include "Dexmedetomidine versus Midazolam for End-of-Life Sedation: The DREAMS Non-Blinded Randomized Clinical Trial" (2025), "Connexins 43 and 45 hemichannels mediate ATP release in the urinary bladder" (2025), "Seasonal trends in antimicrobial resistance of urinary Escherichia coli isolates" (2025), "Uropathogenic Escherichia coli causes significant urothelial damage in an ex vivo porcine bladder model" (2024), "Role of fesoterodine in the treatment of overactive bladder" (2009), and "Muscarinic receptor antagonists, the overactive bladder and efficacy against urinary urgency". Her scholarship influences clinical management of urological conditions, antibiotic stewardship, medical nutrition training, and equitable health workforce distribution in rural Australia.